The changing epidemiology of human monkeypox—A potential threat? A systematic review
Summary
Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the Democratic Republic of the Congo (DRC), it has spread to other regions of Africa (primarily West and Central), and cases outside Africa have emerged in recent years. We conducted a systematic review of peer-reviewed and grey literature on how monkeypox epidemiology has evolved, with particular emphasis on the number of confirmed, probable, and/or possible cases, age at presentation, mortality, and geographical spread. The review is registered with PROSPERO (CRD42020208269). We identified 48 peer-reviewed articles and 18 grey literature sources for data extraction. The number of human monkeypox cases has been on the rise since the 1970s, with the most dramatic increases occurring in the DRC. The median age at presentation has increased from 4 (1970s) to 21 years (2010–2019). There was an overall case fatality rate of 8.7%, with a significant difference between clades—Central African 10.6% (95% CI: 8.4%– 13.3%) vs. West African 3.6% (95% CI: 1.7%– 6.8%). Since 2003, import- and travel-related spread outside of Africa has occasionally resulted in outbreaks. Interactions/activities with infected animals or individuals are risk behaviors associated with acquiring monkeypox. Our review shows an escalation of monkeypox cases, especially in the highly endemic DRC, a spread to other countries, and a growing median age from young children to young adults. These findings may be related to the cessation of smallpox vaccination, which provided some cross-protection against monkeypox, leading to increased human-to-human transmission. The appearance of outbreaks beyond Africa highlights the global relevance of the disease. Increased surveillance and detection of monkeypox cases are essential tools for understanding the continuously changing epidemiology of this resurging disease.
Key Points
- 1Monkeypox cases have significantly risen since the 1970s, particularly in the Democratic Republic of the Congo
- 2The median age of presentation has increased from four years in the 1970s to twenty-one years in the 2010s
- 3The case fatality rate differs by clade, with Central African cases showing higher mortality
- 4The cessation of smallpox vaccinations has likely contributed to increased human-to-human transmission
- 5Increased detection and surveillance are essential for addressing the global relevance of monkeypox.
Related articles
GASTROINTESTINAL AND HEPATOBILIARY SYSTEM DRUGS
This document provides an overview of various drugs affecting the gastrointestinal and hepatobiliary systems, detailing their classifications, mechanisms, and therapeutic uses. It aims to educate students on common medications available in the pharmaceutical market.
How to Assess the Quality of Qualitative Research
This article serves as a guide for health care practitioners, educators, and researchers on how to evaluate the quality of qualitative research. It discusses essential characteristics that make a qualitative study high-quality and trustworthy, as well as standards specific to this type of research.
CHOLEGRAPHY Easy Visual Reviewer - Terms & Definitions Matrix Based on Module
This document serves as an educational resource on cholegraphy, outlining procedures, indications, contraindications, and care related to the imaging of the biliary system. It is designed as a visual reviewer for learners in health sciences.
Routine CT Procedures and Related Anatomy Visual Study Reviewer Matrix
This document serves as a comprehensive reviewer for technologists involved in routine CT examinations, detailing essential procedures, patient preparations, and anatomical landmarks essential for accurate imaging.
Investigating Genetic Counselors' Inclusion of Sponsored Genetic Testing Programs
This study aims to investigate genetic counselors' awareness and attitudes toward sponsored genetic testing programs, as well as the factors influencing their decisions to offer these tests to patients. The importance of understanding these dynamics arises amid the growing availability of biopharmaceutical-sponsored genetic tests and the impact of financial considerations on patient access to care.